huahaipharm(SH:600521)2019-10-30 16:00Financial Performance - Net profit attributable to shareholders of the listed company was ¥511,789,279.65, representing a 100.40% increase year-on-year[5]. - Operating income for the period was ¥4,011,595,028.26, reflecting a growth of 4.39% compared to the same period last year[5]. - Basic earnings per share rose to ¥0.41, a 105.00% increase from ¥0.20 in the same period last year[5]. - The company reported a significant increase in net assets attributable to shareholders, which reached ¥5,556,205,568.69, up 36.52% from the previous year[5]. - The net profit attributable to shareholders increased to ¥511,789,279.65, reflecting a growth of 100.40% driven by improved product pricing and increased technical service income[12]. - The company reported a gross profit margin of approximately 10.7% for Q3 2019, compared to 10.4% in Q3 2018[21]. - Net profit for Q3 2019 was ¥191,242,716.84, compared to ¥44,166,822.03 in Q3 2018, marking a significant increase[22]. - The total profit for Q3 2019 was ¥216.40 million, compared to ¥56.76 million in Q3 2018, marking an increase of 281.5%[25]. Cash Flow - The net cash flow from operating activities for the year-to-date was ¥1,252,277,542.83, a significant recovery from a negative cash flow of ¥19,930,144.63 in the previous year[5]. - Net cash flow from operating activities reached ¥1,252,277,542.83, a significant improvement from a negative cash flow of ¥19,930,144.63 in the previous year[28]. - Total cash inflow from operating activities was ¥4,802,980,885.91, compared to ¥4,069,189,147.99 in the same period last year, reflecting a year-over-year increase of approximately 18%[28]. - Cash outflow from operating activities decreased to ¥3,550,703,343.08 from ¥4,089,119,292.62, indicating improved operational efficiency[28]. - The net cash flow from operating activities for the first three quarters was ¥1,411,193,392.06, a significant recovery from a negative cash flow of ¥6,091,379.21 in the previous year[30]. Assets and Liabilities - Total assets at the end of the reporting period reached ¥11,796,551,013.53, an increase of 13.78% compared to the end of the previous year[5]. - Total liabilities increased to ¥5,638,485,650.97 in Q3 2019 from ¥4,048,270,926.99 in Q3 2018, representing a growth of 39.2%[20]. - Current liabilities rose to ¥5,072,949,374.55 from ¥4,766,261,439.92, reflecting an increase of approximately 6.4%[18]. - Total liabilities reached approximately ¥6.16 billion, while total equity amounted to approximately ¥4.21 billion[36]. - Total non-current assets amounted to approximately 4.995 billion, contributing to total assets of approximately 8.858 billion[39]. Shareholder Information - The total number of shareholders at the end of the reporting period was 47,121[7]. - Major shareholder Chen Baohua held 25.14% of the shares, with 332,452,668 shares pledged[7]. - Total equity attributable to shareholders increased to ¥5,556,205,568.69 from ¥4,069,749,515.63, representing a growth of approximately 36.5%[18]. Investment and Expenses - Investment income showed a loss of ¥16,130,936.56, worsening by 76.88% due to increased losses from associates and joint ventures[12]. - R&D expenses for Q3 2019 amounted to ¥118,670,071.37, an increase of 19.3% from ¥99,468,976.13 in Q3 2018[21]. - The company’s financial expenses for Q3 2019 were ¥26.69 million, a decrease from ¥27.54 million in Q3 2018[24]. - The company reported a long-term investment of approximately 2.107 billion in equity investments[39]. Changes in Financial Position - The company reported a significant decrease in other payables, down to ¥185,975,702.77 from ¥1,136,205,883.75, a reduction of 83.63% due to equity payments[11]. - The capital reserve increased to ¥1,160,436,819.22 from ¥264,107,961.42, a rise of 339.38% attributed to the completion of a private placement[11]. - The company executed adjustments in financial reporting, reclassifying certain financial assets under new accounting standards, impacting the reported values of other comprehensive income[37].